Success Stories: Chinese Postdoctoral Fellow in Illinois in the Field of Biomedical Sciences Secures EB-1A Petition Approval in Just 2 Days

Client’s Testimonial:

“Thanks for all your effort and help on my case.”

On September 2^nd, 2016, we received another EB-1A (Alien of Extraordinary Ability) approval for a Postdoctoral Fellow in the Field of Biomedical Sciences (Approval Notice).

General Field: Biomedical Sciences

Position at the Time of Case Filing: Postdoctoral Fellow

Country of Origin: China

Service Center: Nebraska Service Center (NSC)

State of Residence at the Time of Filing: Illinois

Approval Notice Date: September 2^nd, 2016

Processing Time: 2 Days (Premium Processing Requested)

Case Summary:

Our client’s Ph.D. in Genomics and Drug Discovery served as proof that he is armed with the knowledge and skills required to carry out impactful research in the field of biomedical sciences. Even so, when he approached us for help to file an EB-1A (Alien of Extraordinary Ability) petition on his behalf, we carefully evaluated his credentials to be sure that we could build a strong case for him. After confirming that we could, an attorney-client relationship was established and we got to work on our client’s case.

There is no denying that putting together a strong EB-1A petition is no easy feat. It took us several months in total but judging from the approval notice that our client received merely 2 days after filing, we did an excellent job. The meticulous effort that we put into presenting our client’s solid credentials was not the only thing that accounted for the short wait time—it was mostly thanks to Premium Processing (PP), an add-on option offered by the USCIS that allows petitioners to have their cases processed within 15 calendar days instead of the usual 4-9 months. In any case, we have no doubt that our client’s strong petition paved the way for case approval. These are some of the highlights:

We noted our client’s 6 publications, the 17 times he assessed the work of his peers, and the 193 times his work was cited by other researchers.
Furthermore, we incorporated recommendation letters volunteered by other influential members of the biomedical sciences research community. According to one of them: “Given his high research productivity and continuous record of novel discovery, I can confidently state that [Client] is at the forefront of his field and will continue to produce foundational work in the worldwide realm of biomedical research, particularly within the specialized arena of molecular immunity.”
We duly documented our client’s work on elucidating the role of transcription factor Miz1 and the part it plays in acute lung injury, precisely how kinase JNK2 lends itself to stress-induced mitophagy, conducting incisive examinations on the E3 ligase Mule and its agency in inducing the activation of JNK, and the screening of natural compounds for viable anti-viral candidates, thereby fostering the incorporation of traditional Chinese medicine into the modern drug discovery pipeline for critical vaccine implementation. We proved to the USCIS that our client’s research addresses some of the US’ most pressing issues in understanding the underlying molecular machinery that drives inflammation resolution and cellular death.

We congratulate our client for surpassing this significant hurdle in the green card process. He is now closer to a green card and we wish him the best as he files I-485 applications for himself and his wife. Once the USCIS approves their applications, they will become American permanent residents. Till then, we bid him well as he continues to conduct important research in the field of biomedical sciences.

North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Ten Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With more than 47,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Hundreds and Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our approved cases grew from 600 in 2013 to over 47,000 in 2023.